Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 611 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with... July 1, 2025 EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib August 16, 2024 Breast-Cancer Mom Is Living On 84 Pence As She Fights For... April 15, 2019 Popular Fitness Blogger Maria Kang Removed Her Breast Implants Due To... August 15, 2019 Load more HOT NEWS Female Representation at the Top of the Oncology Field Has Hit... Olivia Newton-John Shares Positive News On Breast Cancer: “I’m Winning Over... Addressing Common Sexual Health Concerns During Cancer Survivorship: An Expert Perspective Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer
